Identificador persistente para citar o vincular este elemento: http://hdl.handle.net/10553/136162
Campo DC Valoridioma
dc.contributor.authorSánchez-Marteles, Martaen_US
dc.contributor.authorGarcés-Horna, Vanesaen_US
dc.contributor.authorMorales-Rull, José Luísen_US
dc.contributor.authorCasado, Jesúsen_US
dc.contributor.authorCarrera-Izquierdo, Margaritaen_US
dc.contributor.authorConde Martel, Aliciaen_US
dc.contributor.authorDávila-Ramos, Melitón Franciscoen_US
dc.contributor.authorLlácer, Pauen_US
dc.contributor.authorSalamanca-Bautista, Pradoen_US
dc.contributor.authorRuiz, Raúlen_US
dc.contributor.authorAramburu-Bodas, Oscaren_US
dc.contributor.authorFormiga, Francescen_US
dc.contributor.authorManzano, Luísen_US
dc.contributor.authorTrullàs, Joan Carlesen_US
dc.date.accessioned2025-02-13T15:46:02Z-
dc.date.available2025-02-13T15:46:02Z-
dc.date.issued2024en_US
dc.identifier.issn2213-1779en_US
dc.identifier.urihttp://hdl.handle.net/10553/136162-
dc.description.abstractBackground: The addition of hydrochlorothiazide (HCTZ) to furosemide in the CLOROTIC (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure) trial improved the diuretic response in patients with acute heart failure (AHF). Objectives: This work aimed to evaluate if these results differ across the spectrum of left ventricular ejection fraction (LVEF). Methods: This post hoc analysis of the randomized, double-blind, placebo-controlled CLOROTIC trial enrolled 230 patients with AHF to receive either HCTZ or a placebo in addition to an intravenous furosemide regimen. The influence of LVEF on primary and secondary outcomes was evaluated. Results: The median LVEF was 55%: 166 (72%) patients had LVEF >40%, and 64 (28%) had LVEF ≤40%. Patients with a lower LVEF were younger, more likely to be male, had a higher prevalence of ischemic heart disease, and had higher natriuretic peptide levels. The addition of HCTZ to furosemide was associated with the greatest weight loss at 72 of 96 hours, better metrics of diuretic response, and greater 24-hour diuresis compared with placebo, with no significant differences according to the LVEF category (using 2 LVEF cutoff points: 40% and 50%) or LVEF as a continuous variable (all P values were insignificant). There were no significant differences observed with the addition of HCTZ in terms of mortality, rehospitalizations, or safety endpoints (impaired renal function, hyponatremia, and hypokalemia) among the 2 LVEF groups (all P values were insignificant). Conclusions: Adding HCTZ to intravenous furosemide seems to be effective strategy for improving diuretic response in AHF without treatment effect modification according to baseline LVEF. (Combining Loop with Thiazide Diuretics for Decompensated Heart Failure [CLOROTIC], NCT01647932; Randomized, double blinded, multicenter study, to asses Safety and Efficacy of the Combination of Loop With Thiazide-type Diuretics vs Loop diuretics with placebo in Patients With Decompensated, EudraCT Number 2013-001852-36)en_US
dc.languageengen_US
dc.relation.ispartofJACC: Heart Failureen_US
dc.sourceJACC: Heart Failure [ISSN 2213-1779], v. 12 (10), pp. 1719-1730en_US
dc.subject32 Ciencias médicasen_US
dc.subject3205 Medicina internaen_US
dc.subject320501 Cardiologíaen_US
dc.subject.otherAcute heart failureen_US
dc.subject.otherDiureticsen_US
dc.subject.otherHydrochlorothiazideen_US
dc.subject.otherLeft ventricular ejection fractionen_US
dc.subject.otherThiazidesen_US
dc.titleCombining Loop and Thiazide Diuretics Across the Left Ventricular Ejection Fraction Spectrum: The CLOROTIC Trialen_US
dc.typeArticleen_US
dc.identifier.doi10.1016/j.jchf.2024.05.006en_US
dc.identifier.pmid38934966-
dc.identifier.scopus2-s2.0-85189612835-
dc.contributor.orcid0000-0001-9067-2158-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.contributor.orcid#NODATA#-
dc.description.lastpage1730en_US
dc.identifier.issue10-
dc.description.firstpage1719en_US
dc.relation.volume12en_US
dc.investigacionCiencias de la Saluden_US
dc.type2Artículoen_US
dc.description.notasSafety and Efficacy of the Combination of Loop With Thiazide-type Diuretics in Patients With Decompensated Heart Failure (CLOROTIC)en_US
dc.utils.revisionen_US
dc.identifier.ulpgcen_US
dc.contributor.buulpgcBU-MEDen_US
dc.description.sjr5,724
dc.description.jcr13,0
dc.description.sjrqQ1
dc.description.jcrqQ1
dc.description.scieSCIE
dc.description.miaricds10,4
item.fulltextCon texto completo-
item.grantfulltextopen-
crisitem.author.deptGIR IUIBS: Patología y Tecnología médica-
crisitem.author.deptIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.deptDepartamento de Ciencias Médicas y Quirúrgicas-
crisitem.author.orcid0000-0002-2540-3880-
crisitem.author.parentorgIU de Investigaciones Biomédicas y Sanitarias-
crisitem.author.fullNameConde Martel, Alicia-
Colección:Artículos
Adobe PDF (828,25 kB)
Vista resumida

Citas SCOPUSTM   

2
actualizado el 16-feb-2025

Citas de WEB OF SCIENCETM
Citations

1
actualizado el 16-feb-2025

Google ScholarTM

Verifica

Altmetric


Comparte



Exporta metadatos



Los elementos en ULPGC accedaCRIS están protegidos por derechos de autor con todos los derechos reservados, a menos que se indique lo contrario.